NVAX
NASDAQ · Biotechnology
Novavax Inc
$9.62
-0.12 (-1.23%)
Financial Highlights (FY 2026)
Revenue
749.60M
Net Income
-206,034,504
Gross Margin
70.4%
Profit Margin
-27.5%
Rev Growth
-15.9%
D/E Ratio
0.75
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 70.4% | 70.4% | 63.1% | 63.1% |
| Operating Margin | -36.5% | -32.8% | -1.5% | -1.6% |
| Profit Margin | -27.5% | -26.1% | -1.5% | -1.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 749.60M | 891.22M | 441.16M | 496.93M |
| Gross Profit | 527.94M | 627.68M | 278.28M | 313.45M |
| Operating Income | -273,529,412 | -292,683,950 | -6,707,375 | -7,754,591 |
| Net Income | -206,034,504 | -220,462,553 | -6,729,988 | -7,016,912 |
| Gross Margin | 70.4% | 70.4% | 63.1% | 63.1% |
| Operating Margin | -36.5% | -32.8% | -1.5% | -1.6% |
| Profit Margin | -27.5% | -26.1% | -1.5% | -1.4% |
| Rev Growth | -15.9% | -15.9% | +6.7% | +13.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 365.72M | 365.72M | 676.10M | 713.41M |
| Total Equity | 490.11M | 490.11M | 690.04M | 696.43M |
| D/E Ratio | 0.75 | 0.75 | 0.98 | 1.02 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -118,720,693 | -134,091,853 | -8,036,743 | -8,599,324 |
| Free Cash Flow | — | — | -9,195,591 | -10,064,458 |